Lakefront Biotherapeutics NV 0JXZ.IL · Stock Open Lakefront Biotherapeutics NV in new tab
Lakefront Biotherapeutics NV Analysis (0JXZ.IL)
Is Lakefront Biotherapeutics NV a good investment? Lakefront Biotherapeutics NV (0JXZ.IL) is currently trading at 26.15 EUR.
Investor FAQ
Does Lakefront Biotherapeutics NV pay a dividend?
No, it does not currently pay a dividend.
What asset class is Lakefront Biotherapeutics NV?
Lakefront Biotherapeutics NV is classified as a Stock. You can compare it against 8 other assets in the "Related Symbols" list on this page.
Company Profile
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of?various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG3667 that has completed Phase 1b trial; and GLPG5101 and GLPG5201, CD19 CAR-T product candidate manufactures at point-of-care, that is in Phase I/II in relapsed/refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Community Discussion